Skip to main content
. 2022 Jun 15;21:107. doi: 10.1186/s12933-022-01542-4

Fig. 6.

Fig. 6

Meta-regression analysis for the interaction of difference between PCSK9 inhibitors group and control group in LDL-C level change on the risk of new-onset diabetes. LDL-C low-density lipoprotein cholesterol, PCSK9 proprotein convertase subtilisin/kexin 9